{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:48Z","timestamp":1789726248529,"version":"4.0.1"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJHP"],"abstract":"<jats:p>Background: Given altered pharmacokinetics in people with cystic fibrosis (pwCF), there is debate regarding optimal strategies for therapeutic drug monitoring (TDM) for aminoglycosides and vancomycin administered intravenously.\nObjectives: To determine the TDM strategy for IV aminoglycosides and IV vancomycin associated with optimal clinical outcomes in pwCF.Data Sources: Several databases (MEDLINE, Embase, CINAHL, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov) were searched from inception to November 15, 2020, with searches rerun on February 13, 2023. \nStudy Selection and Data Extraction: Full articles evaluating TDM strategies and clinical outcomes in pwCF receiving IV aminoglycosides or IV vancomycin were included. \nData Synthesis: Three studies met the inclusion criteria for IV aminoglycosides, and 1 study met the inclusion criteria for IV vancomycin. Data are presented with descriptive analyses. \nConclusions: The available evidence is insufficient to determine an optimal TDM strategy for IV aminoglycoside or IV vancomycin therapy in\u00a0pwCF.\nR\u00c9SUM\u00c9\nContexte\u00a0: \u00c9tant donn\u00e9 que la pharmacocin\u00e9tique des personnes atteintes de fibrose kystique est alt\u00e9r\u00e9e, un d\u00e9bat existe concernant les strat\u00e9gies optimales de suivi th\u00e9rapeutique des m\u00e9dicaments (STM) pour les aminoglycosides et la vancomycine administr\u00e9s par voie intraveineuse.\nObjectif\u00a0: D\u00e9terminer la strat\u00e9gie de suivi th\u00e9rapeutique des m\u00e9dicaments pour les aminoglycosides et la vancomycine par voie intraveineuse associ\u00e9e aux r\u00e9sultats cliniques optimaux chez les personnes atteintes de fibrose kystique.\nSources des donn\u00e9es\u00a0: Plusieurs bases de donn\u00e9es (MEDLINE, Embase, CINAHL, Web of Science, Cochrane Central Register of Controlled Trials et ClinicalTrials.gov) ont \u00e9t\u00e9 consult\u00e9es depuis leur cr\u00e9ation jusqu\u2019au 15 novembre 2020, avec des recherches r\u00e9p\u00e9t\u00e9es le 13 f\u00e9vrier 2023.\nS\u00e9lection des \u00e9tudes et extraction des donn\u00e9es\u00a0: Les articles en texte int\u00e9gral \u00e9valuant les strat\u00e9gies de suivi th\u00e9rapeutique des m\u00e9dicaments et les r\u00e9sultats cliniques chez les personnes atteintes de fibrose kystique recevant des aminoglycosides ou de la vancomycine par voie intraveineuse ont \u00e9t\u00e9 inclus.\nSynth\u00e8se des donn\u00e9es\u00a0: Trois \u00e9tudes r\u00e9pondaient aux crit\u00e8res d\u2019inclusion pour les aminoglycosides par voie intraveineuse, et une \u00e9tude r\u00e9pondait aux crit\u00e8res d\u2019inclusion pour la vancomycine par voie intraveineuse. Les donn\u00e9es s\u2019accompagnent d\u2019analyses descriptives.\nConclusions\u00a0: Les \u00e9l\u00e9ments probants disponibles sont insuffisants pour d\u00e9terminer une strat\u00e9gie optimale de suivi th\u00e9rapeutique des m\u00e9dicaments pour la th\u00e9rapie par aminoglycosides par voie intraveineuse ou la vancomycine par voie intraveineuse chez les personnes atteintes de fibrose kystique.<\/jats:p>","DOI":"10.4212\/cjhp.3429","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:35:56Z","timestamp":1696347356000},"page":"317-323","source":"Crossref","is-referenced-by-count":1,"title":["Optimal Therapeutic Drug Monitoring Strategy for IV Aminoglycosides and IV Vancomycin in People with Cystic Fibrosis: A Systematic Review"],"prefix":"10.4212","volume":"76","author":[{"given":"Jessie","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Giunio-Zorkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Dagenais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2732","published-online":{"date-parts":[[2023,10,2]]},"container-title":["Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3429\/5041","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3429\/5065","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3429\/5041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:35:56Z","timestamp":1696347356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/3429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,10,2]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.3429","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"value":"1920-2903","type":"electronic"},{"value":"0008-4123","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,2]]}}}